7,120 reports of this reaction
3.3% of all CARBOPLATIN reports
#2 most reported adverse reaction
NEUTROPENIA is the #2 most commonly reported adverse reaction for CARBOPLATIN, manufactured by Accord Healthcare, Inc.. There are 7,120 FDA adverse event reports linking CARBOPLATIN to NEUTROPENIA. This represents approximately 3.3% of all 214,224 adverse event reports for this drug.
Patients taking CARBOPLATIN who experience neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NEUTROPENIA is moderately reported among CARBOPLATIN users, representing a notable but not dominant share of adverse events.
In addition to neutropenia, the following adverse reactions have been reported for CARBOPLATIN:
The following drugs have also been linked to neutropenia in FDA adverse event reports:
NEUTROPENIA has been reported as an adverse event in 7,120 FDA reports for CARBOPLATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
NEUTROPENIA accounts for approximately 3.3% of all adverse event reports for CARBOPLATIN, making it one of the most commonly reported side effect.
If you experience neutropenia while taking CARBOPLATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.